- Home
- ORIS vs GRI Comparison
ORIS vs GRI Comparison
Compare ORIS & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- GRI
- Stock Information
- Founded
- ORIS 2014
- GRI 2018
- Country
- ORIS China
- GRI United States
- Employees
- ORIS N/A
- GRI N/A
- Industry
- ORIS Farming/Seeds/Milling
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ORIS Consumer Staples
- GRI Health Care
- Exchange
- ORIS Nasdaq
- GRI Nasdaq
- Market Cap
- ORIS 5.3M
- GRI 4.9M
- IPO Year
- ORIS 2024
- GRI N/A
- Fundamental
- Price
- ORIS $0.14
- GRI $1.94
- Analyst Decision
- ORIS
- GRI Strong Buy
- Analyst Count
- ORIS 0
- GRI 2
- Target Price
- ORIS N/A
- GRI $22.50
- AVG Volume (30 Days)
- ORIS 5.1M
- GRI 203.7K
- Earning Date
- ORIS 01-01-0001
- GRI 11-13-2025
- Dividend Yield
- ORIS N/A
- GRI N/A
- EPS Growth
- ORIS N/A
- GRI N/A
- EPS
- ORIS 0.17
- GRI N/A
- Revenue
- ORIS $15,014,000.00
- GRI N/A
- Revenue This Year
- ORIS N/A
- GRI N/A
- Revenue Next Year
- ORIS N/A
- GRI N/A
- P/E Ratio
- ORIS $0.85
- GRI N/A
- Revenue Growth
- ORIS N/A
- GRI N/A
- 52 Week Low
- ORIS $0.08
- GRI $1.10
- 52 Week High
- ORIS $56.01
- GRI $22.95
- Technical
- Relative Strength Index (RSI)
- ORIS 42.26
- GRI 49.33
- Support Level
- ORIS $0.14
- GRI $1.89
- Resistance Level
- ORIS $0.15
- GRI $2.27
- Average True Range (ATR)
- ORIS 0.01
- GRI 0.16
- MACD
- ORIS -0.00
- GRI -0.01
- Stochastic Oscillator
- ORIS 4.91
- GRI 32.65
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.